+34 679 490 537info@nanbiosis.com

Nanbiosis

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone
Ciber bbn

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dra. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC
IQAC CSIC
Order request

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus.Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

Active projects

TitleFundin: OrganismCall: Funding source Role
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Partner
PICCOLO-732111Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision supportEuropean Commission-H2020H2020-ICT-2016-1Partner
0624_2IQBIONEURO_6_EPromotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseasesEuropean Union Interreg : European Territorial Co-operationPOCTEP Interreg España-PortugalPartner

Other projects

RefTitleFunding OrganismUnit Role
SAF2015-67476-RImmunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS)Ministerio de Economía y CompetitividadParticipant
PIE1400061Molecular links between diabetes and neurodegenerative diseasesISCIIIOberver
2014SGR1484Consolidated Research GroupGeneralitat de CatalunyaParticipant
FP7-614168Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP)European CommissionOberver
CI16-00031 Caixa ImpulseA new approach for the detection of Pseudomonas aeruginosaCaixaBankParticipant
MSCA-ITN2015-675412New Diagnostics for Infectious DiseasesEuropean CommissionParticipant
TECCTP15-1-0011Ajuda acreditació Tecnio del grup Nb4DACCIÓ: Generalitat de CatalunyaOthers

Publications

2016

  • Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
  • Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
  • Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

29 Nov

Nb4D group- NANBIOSIS U2 receives the acreditation TECNICO, in the on line event organizes by ACCIO

Las November 27 was held the ACCIO ceremony (on line this year due to the Covid Pandemic restrictions) of disclosure of new TECNIO accreditations. Aurea Rodriguez, Director of Business Innovation at ACCIO has welcomed the attendees to the event. Later, the TECNIO program Coordinator, Marta Peidro, presented the background and rationale for this accreditation for excellence groups in technology transfer in Catalonia. This year there have been five new groups from among all Catalan universities and research organizations, which have obtained the TECNIO accreditation for the first time, making a total of fifty-four groups accredited in 2020. The event continued[...]

13 Nov

Nb4D group – NANBIOSIS Unit 2 CAbS – accredited with the TECNIO seal

The Nb4D group of CIBER-BBN and IQAB-CSIC, coordinator of NANBIOSIS Unit 2 Custom Antibody Service (CAbS), has been accredited with the TECNIO seal. This accreditation is the hallmark TECNIO granted by the Government of Catalonia, through ACCIÓ, to identify the developers and facilitators of differential technologies in Catalonia. TECNIO is the umbrella brand for catalan technology centres and university research groups dedicated to industrial research and technology transfer. ACCIO, CERTIFICATION, QUALITY MANAGEMENT SYSTEM[...]

02 Nov

Prof. Pilar Marco, in the program “Meridiano Turing” of RTVE explains the COVID-19 tests.

The last edition of the program “Meridiano Turing” of RTVE interviews Maria Pilar Marco Head of CIBER-BBN and IQAC-CSIC group Nb4D and NANBIOSIS-ICTS Unit 2 Custom Antibody Service (CAbS), Cesar Fernández (Head of the Chemical Transducers Group at IMB-CNM, CSIC) and María Cruz Minguillón (EGAR group at IDAEA) Pilar Marco y César Fernández, the authors of the block of the CSIC’s report entitled “Containment and diagnosis“, explain wich is the best way to diagnose COVID and how reliable are the tests in this moment. What is needed is to detect an infection -says Pilar Marco- is viral material and w[...]

02 Oct

New updated version of the CSIC report on COVID-19

The report by Spanish Higher Council for Scientific Research (CSIC) summarizng the most relevant scientific results on the Covid-19 pandemic.  “A global vision of the Covid-19 pandemic: What we know and what we are investigating from CSIC”, has just published its version number 4. This report is structured in five blocks: prevention, disease, containment and diagnosis, treatment and vaccines, and global impact. The containment and diagnosis block describes how the virus is transmitted in the air indoors and the analysis of wastewater as a system for early detection of SARS-CoV-2 is explained. In addition, the importance of diagnosis in t[...]

21 Sep

NANBIOSIS Expertise in the IQAC-CSIC Symposium dedicated to the fight against Covid-19 Pandemic

The 4th Annual IQAC Symposium will take place on September 23, 2020. This year will be dedicated to the research projects on COVID-19 that are being carried out in the IQAC-CSIC. It will be a dissemination day aiming to inform the general public about some of the lines of research that are currently being developed in the fight against the COVID-19 pandemic. The event will be live streamed in Facebook: facebook.com/iqac.csic.es/ Three of the speakers, members of CIBER-BBN NANBIOSIS units at IQAC-CSIC, will explain their work. Pilar Marco and Roger Galve (NANBIOSIS U2 Custom Antibody Service (CAbS) will talk about[...]

12 Aug

NANBIOSIS U2 expands its capabilities with a two new equpipments

The U2 of NANBIOSIS, Custom Antibody Service (CAbS) has expanded its capabilities with two new equipment items an Automated microdispensing system for microarray technology and a Nitrogen Tank Cryomemo. The Automated microdispensing system for microarray technology is a sciFLEXARRAYER S3 is an automated piezo driven, non-contact dispensing system of ultra-low volumes specifically designed as an economical entry unit for academia and R&D labs. It consists of XYZ-stages with spindle drives, a piezo dispensing unit and precision equipment for liquid handling. The system handles volumes from 50 picoliters up to several microliters. The S3 is suitable for the production  DNA, protein,[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

01 Jun

New methods to detect Coronavirus: interactive webinar on the diagnosis of COVID-19

CSIC has orgnized an interactive webinar on new COVID-19 detection systems that brings together biotechnologist Luis Blanco, nanotechnologists Laura Lechuga and Pilar Marco, and physicist Javier Tamayo . Researchers from the Higher Council for Scientific Research (CSIC) will answer citizens’ questions about the diagnostic methods of the SARS-CoV-2 coronavirus, which causes Covid-19, in a webinar or interactive debate that will be broadcast on Wednesday, June 3, at 8:15 p.m., on the CSIC YouTube channel. The meeting will feature the participation of biotechnologist Luis Blanco, the physicist Javier Tamayo and the nanotechnologists Laura Lechuga, Scientific Director of NANBIOSIS unti 4 Biodeposition[...]

U2-Custom Antibody Service (CAbS)
Read More

U4. Biodeposition and Biodetection Unit

Ciber bbn

U4. Biodeposition and Biodetection Unit

  • Scientific Director: Prof. Laura Lechuga laura.lechuga@icn2.cat
  • Scientific Coordinator: Dr. MªCarmen Estevez mcarmen.estevez@icn2.cat
  • Entities: Research Center on Nanoscience and Nanotechnology CIN2 & CSIC
  • Address: Campus Bellaterra, 08193 Cerdanyola del Vallés, Barcelona, Spain
  • Service Contact mail: nanob2a@icn2.cat
  • Phone: +34 937 374 617
  • Web: CIN2

CIN2_U4 CSIC

Order request

Description

Located at the Research Center onNanoscience and Nanotechnology(CIN2), CSIC, at the campus of Universidad Autónoma de Barcelona (UAB) the Biodeposition Unit consists of a versatile and automated molecular printer that can dispense minute volumes of solutions (from atto to femtoliter volumes) on a wide variety of surfaces to create user-defined patterns of spots or lines with high spatial resolution. The system is suitable for the functionalization of biosensors with any kind of biomolecule, nanoparticles, graphene or other nanostructures,for surface patterning for cell culture, or for the preparation of micro/nanoarrays, among other applications. The laboratory also harbors a Surface Plasmon Resonance (SPR) service. The Unit is coordinated by Prof. LauraM. Lechuga, group leader from the Nanobiosensorsand Bioanalytical Applications Group (nanoB2A) at CIN2-CSIC.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U4. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
H2020-ICT-2014-1 - 644956 Scalable point-of-care and label free microarray platform for rapid detection of sepsis Comisión Europea Others
TEC2016-78515-R Point-of-care Nanoplasmonic Platforms for Novel High-Value Diagnostics and Therapy Follow-Up (PreDICT) MINECO Others

Publications

2016

  • Avino A., Huertas C.S., Lechuga L.M., Eritja R.. Sensitive and label-free detection of miRNA-145 by triplex formation. Analytical and Bioanalytical Chemistry. 2016;:1-9.

News U4

30 Nov

2020 Rei Jaume I Awards ceremony – Laura Lechuga NANBIOSIS U4-

This monday 30 of october has taken place the traditional ceremony of Rei Jaume I Awards in Valencia, granted to six professionals in research, science and economics. At the ceremony, the awards have been given to the winners of the six categories: Rei Jaume I Basic Research Prize 2020 to Fco. José García Vidal; Rei Jaume I Economy Prize 2020 to Diego Puga; Rei Jaume I Medical Research Prize 2020 to Miguel Beato del Rosal; Rei Jaume I Environmental Protection Award 2020 to Fernando T. Maestre; Rei Jaume I New Technologies Award 2020 to Laura Lechuga and Rei Jaume I[...]

23 Nov

NANBIOSIS-ICTS AT CASEIB 2020

The XXXVII Annual Congress of the Spanish Society of Biomedical Engineering (CASEIB) is taking place between November 25 and 27. This new edition of CASEIB, in virtual format is organized by the CIBER-BBN group of Biomedical Engineering at Valladolid Universitiy, led by Prof. Roberto Sánchez Hornero. Prof. Laura Lechuga, Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit, member of the advisoty committee of scientific experts (Multidisciplinary Working Group) to the Ministry of Science and Innovation in COVID-19 and coordinator of the European project CONVAT shall participate in the Roundtable I: Biomedical Engineering and COVID-19 November 26, 12:00 h Researchers of BSICoS[...]

16 Nov

Laura Lechuga: awarded the most important recognition in Spain in the field of scientific research

The Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit Laura Lechuga, has been awarded the 2020 National Research Prize, the most important recognition in Spain in the field of scientific research, granted by the Ministry of Science and Innovation. The National Research Awards, created in 1982, aim to distinguish the merit of those researchers of Spanish nationality who are carrying out outstanding work in scientific fields of international relevance and who exceptionally contribute to the advancement of science, to the transfer of technology and the progress of humanity. These awards have a total amount of 300,000 euros, (30,000 euros[...]

20 Oct

Laura Lechuga awarded the 2020 Rei Jaume I Prize in New Technologies

The Valencian Government (Generalitat Valenciana), together with the Foundation Premios Rei Jaume I, announced today the awardees of the 32th edition of the Rei Jaume I Awards, one of the highest recognitions for a research career in Spain. Prof. Laura M. Lechuga Gomez, Full Professor of the Spanish National Research Council (CSIC), head of the NANBIOSIS U4 Biodeposition and Biodetection Unit  and the Nanobiosensors and Bioanalytical Applications Group (of CIBER-BBN and the ICN2), has received the New Technologies Award. Prof. Laura M. Lechuga received her PhD in Chemistry from the University Complutense of Madrid (Spain) in 1992. The principal focus of her researc[...]

18 Oct

Women Technologist Ada Byron Award to Laura Lechuga, Scientific Director of NANBIOSIS U4.

The organizing committee and jury of the seventh edition of the Ada Byron Prize for Technological Women, from the Faculty of Engineering of the University of Deusto, have awarded the 2020 award to Prof. Laura Lechuga Scientific Director of Nanbiosis U4 Biodeposition and Biodetection Unit of ICN2-CSIC and CIBER-BBN. Laura Lechuga has a degree in Chemical Sciences and is currently a research professor at the CSIC of Barcelona, Head of the Group of Nanobiosensors and Bioanalytical Applications. Her research area focuses on Nanomedicine, Nanodiagnosis and the technological development of nanophotonic biosensors and their integration into portable Point-of-Care (POC) platforms, as[...]

23 Sep

How Nanophotonic Label-Free Biosensors Can Contribute to Rapid and Massive Diagnostics of Respiratory Virus Infections: COVID-19 Case

An accurate and explanatory review recently published in ACS Sensors. led by Prof. Laura Lechuga, Scientific Director of Nanbiosis U4 Biodeposition and Biodetection Unit from CIBER-BBN and ICN2, discusses current diagnostic techniques for COVID-19 and possible future developments in this field. In particular, after highlighting the advantages and limitations of the methods available at present, the article introduces optical biosensors and illustrates how nanophotonic label-free devices can contribute to meet the emerging needs in this context. For further information at ICN2 website Reference article: Maria Soler, Maria Carmen Estevez, Maria Cardenosa-Rubio, Alejandro Astua, and Laura M. Lechuga, How Nanophotonic Label-Free Biosensors Can Contribute to Rapid and Massive Diagnostics of Respiratory[...]

24 Aug

Upgrade of UV / Ozone cleaner for NanoeNabler
NANBIOSIS U4 expands its capabilities with a upgrades

NANBIOSIS, U4 Biodeposition and Biodetection Unit has expanded its capabilities with two upgrades: Upgrade of UV / Ozone cleaner for NanoeNabler and Upgrade of the optics and the microfluidic components of the Biodetection Unit (SPR biosensor) This upgrade and new equipment have been confinanced by the European Regional Development Fund (ERDF) through the Plurirregional Operational Program of Spain (POPE)2014-2020[...]

21 Jun

The European Commission releases a video showing the European project against coronavirus led by prof Laura Lechuga

The European Commission Representation in Barcelona has published the five-minute video “The EU fights the Covid-19 from Catalonia” in which four researchers explain the projects they are working on. The researchers appearing in the video are  Laura Lechuga Scientific Director of NANBIOSIS unit 4 from CIBER-BBN and ICN2-CSIC and Group Leader of CIBER-BBN at the ICN2 Nanobiosensors and Bioanalytical Applications Group), who works on a sensor to detect the coronavirus in a faster, easier and cheaper way than with current PCRs, Núria Montserrat (IBEC), who works on micro-kidneys made from stem cells to test a drug able to block the virus, Alfonso Valencia (BSC), who explains[...]

U4-Biodeposition and Biodetection Unit
Read More

U29. Oligonucleotide Synthesis Platform (OSP)

U2 CAbS-hybridoma clone
Ciber bbn

U29. Oligonucleotide Synthesis Platform (OSP)

  • Scientific Director: Prof. Ramon Eritja: recgma@cid.csic.es
  • Scientific Coordinator: Dr. Anna Aviñó: aaagma@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 145
  • Web: IQAC- CSIC
IQAC CSIC
Order request

Description

This unit is coordinated by the Nucleic Acids Chemistry Group at the Institute for Advanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC) and has the equipment needed for the production of oligonucleotides at low scale (mg to mg), purification, characterization and post-synthesis modification. The service counts with laboratories for synthesis and modification of oligonucleotides including DNA/RNA synthesizer, analytical and semi-preparative HPLC equipment for the purification and characterization of oligonucleotides. The service will focus in providing expert opinion to researchers as well as the production of tailored oligonucleotides. Routine synthesis of oligonucleotides used as primers will not be produced as there is a large number of commercial sources that provide a quick and low price service. The oligonucleotide synthesis platform will focus in providing modified oligonucleotides (ONs) that are difficult to obtain from commercial sources. These include microgram to milligram amounts of DNA and RNA derivatives carrying several modifications as well as oligonucleotide conjugates carrying lipids, membrane-receptors ligands, carbohydrates and peptides designed for therapeutic or diagnostic purposes. The facility benefits from the wide experience of Prof. Ramon Eritja that has more than 30 years expertise in the development of modified oligonucleotides.

Active projects

RefTitleFundin OrganismRole
CTQ2017-84415-R STUDY OF ADN STRUCTURES WITH BIOMEDICAL POTENTIALMINECOCoordinator

Other projects

RefTitleFundin OrganismRole
SBPLY/17/180501/000376Development and validation of new intelligent administration systems of RNAs in the injured spinal cord: application in a neuroprotective therapy based on miR-138Junta de Castilla-La Mancha Participant
BIO2017-92113-EXP New tailored microRNA-based antifungal agents for crop protectionMINECO - Explora-Participant
CA17103CA17103 Delivery of antisense RNA therapeutics (DARTER) C.C.E.E. COST Action Participant
AC18/00046Monitoring of Acquired Brain Injury and recovery of biomarkers by the combined label-free NanoSensing of multiple circulating molecules (ABISens).Euronanomed-III (ERA-Net cofund action on Nanomedicine)Participant
CSIC-COV19-041Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV) Consejo Superior de Investigaciones Científicas (CSIC)Participant
Prometeo/2020/081Use of microRNA modulators as experimental therapies in type 1 myotonic dystrophy Generalitat Valenciana Participant

Publications

2019

“Synthesis of oligonucleotides carrying nucleic acid derivatives of biomedical and structural interest” Eritja, R., Aviñó, A., Fàbrega, C., Alagia, A., Jorge, A.F., Grijalvo, S. In “Enzymatic and chemical synthesis of nucleic acid derivatives” (Fernández Lucas and Camarasa Eds) Willey-VCH Verlag, Weinheim (Germany), pp 237-258, (2019).

Cationic niosomes as non-viral vehicles for nucleic acids. Challenges and opportunities in gene delivery. Grijalvo, S., Puras, G., Zárate, J., Sainz-Ramos, M., AL Qtaish, N., López, T., Mashal, M., Attia, N., Díaz Díaz, D., Pons, R., Fernández, E., Pedraz, J.L., Eritja, R.  Pharmaceutics, 11(2), 50 (2019).

“Parallel clamps and polypurine hairpins (PPRH) for gene silencing and triplex-affinity capture: design, synthesis and use” Aviñó, A., Eritja, R., Cuidad, C., Noe, V. Current Protocols on Nucleic Acid Chemistry, e78 (2019).

“Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy” Aviñó, A., Unzueta, U., Cespedes, M.V., Casanova, I., Vázquez, E., Villaverde, A., Mangues, R., Eritja, R. ChemistryOpen, 8, 382-387 (2019).

“The small interfering RNAs (siRNAs) in cancer therapy: nano-based approach” Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C.D., Memari, F., Miri, S.R., Rad, M.R., Marmari, V. Int. J. Nanomedicine, 14, 3111-3128 (2019).

“The origins and the biological consequences of the Pur/Pyr DNA•RNA asymmetry” Terrazas, M., Genna, V., Portella, G., Villegas, N., Sánchez, D., Arnan, C., Pulido-Quetglas, C., Johnson, E., Guigó, R., Brun-Heath, I., Aviñó, A., Eritja, R., Orozco, M. Chem., 5, 1619-1631 (2019).

“On the race for more stretchable and tough hydrogels” Grijalvo, S., Eritja, R., Díaz Díaz, D. Gels, 5, 24 (2019).

“Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes” Mashal, M., Attia, N., Martínez-Navarrete, G., Soto-Sánchez, C., Fernández, E., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Control. Rel., 304, 181-190 (2019).

“Study of conformational transitions of i-motif DNA using time-resolved fluorescence and multivariate analysis methods” Benabou, S., Ruckebusch, C., Sliwa, M., Aviñó, A., Eritja, R., Gargallo, R., de Juan, A.  Nucleic Acids Res., 47, 6590-6605 (2019).

“Expanding the limits of amide-triazole isosteric substitution in bisamide-based physical gels” Tautz, M., Torras, J., Grijalvo, S., Eritja, R., Saldías, C., Alemán, C., Díaz Díaz D. RSC Adv., 9, 20841-20851 (2019).

“Aptamer-peptide conjugates as a new strategy to modulate human α-thrombin binding affinity” Aviñó, A., Jorge, A.F., Huertas, C.S., Cova, T.F.G.G., Pais, A., Lechuga, L.M., Eritja, R., Fàbrega, C. Biochim. Biophys. Acta (General subjects), 1863, 1610-1630 (2019).

“Cationic niosome-based hBMP7 gene transfection of neuronal precursor NT2 cells to reduce the migration of glioma cells in vitro” Attia, N., Mashal, M., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Drug Delivery Science Technol., 53, 101219 (2019).

“Stabilization of c-KIT G-quadruplex DNA structures by the RNA polymerase I inhibitors BMH-21 and BA-41” Mazzini, S., Gargallo, R., Musso, L., De Santis, F., Aviñó, A., Scaglioni, L., Eritja, R., Di Nicola, M., Zunino, F., Amatulli, A., Dallavalle, S. Int. J. Mol. Sci., 20, 4927 (2019).

“Alginate hydrogels as scaffolds and delivery systems to repair the damaged spinal cord” Grijalvo, S., Nieto-Díaz, M., Maza, R.M., Eritja, R., Díaz Díaz, D. Biotech J., 14, e1900275 (2019).

“A pH-dependent bolt involving cytosine bases located in the lateral loops of antiparallel G-quadruplex structures within the SMARCA4 gene promotor” Benabou S., Mazzini, S., Aviñó, A., Eritja, R. Gargallo, R. Sci. Rep., 9, 15807 (2019).

2018

Selective depletion of metastatic stem cells as therapy for human colorectal cancer. Céspedes, M.V., Unzueta, U., Aviñó, A., Gallardo, A., Álamo, P., Sala, R., Sánchez-Sardi, A., Casanova, I., Mangues, M.A., Lopez-Pousa, A., Eritja, R., Villaverde, A., Vázquez, E., Mangues, R. EMBO Mol. Med., 10, e8772 (2018).

DNA-based nanoscaffolds as vehicles for 5-fluoro-2’-deoxyuridine oligomers in colorectal cancer therapy. Jorge, A.F., Aviñó, A., Pais, A.A.C.C., Eritja, R., Fàbrega, C. Nanoscale, 10, 7238-7249 (2018).

Exploring PAZ/3’-overhang interaction to improve siRNA specificity. A combined experimental and modeling study. Alagia, A., Jorge, A.F., Aviño, A., Cova, T.F.G.G., Crehuet, R., Grijalvo, S., Alberto Pais, A.A.C.C., Eritja, R. Chem. Sci., 9, 2074-2086 (2018).

DNA origami-driven lithography for patterning on gold surfaces with sub-10 nanometer resolution. Gállego, I., Manning, B., Prades, J.D., Mir, M., Samitier, J., Eritja, R. Adv. Mat., 29, 1603233 (2017).

Glucose-nucleobase pseudo base pairs as a new biomolecular interaction in a DNA context. Vengut-Climent, E., Gómez-Pinto, I., Lucas, R., Peñalver, P., Aviñó, A., Fonseca-Guerra, C, Bickelhaupt, F.M.., Eritja, R., González, C., Morales, J.C. Angew. Chem. Int. Ed. Engl., 55, 8643-8647 (2016).

News U29

22 Nov

Closer to understand the regulation of SMARCA4 expression

Researchers of NANBIOSIS U29 Oligonucleotide Synthesis Platform (OSP) from CIBERBBN at @IQAC_CSIC, led by Prof. Ramón Eritja, are the authors of an article published by Int J Biol Macromol. 2020, entitled “Influence of pH and a porphyrin ligand on the stability of a G-quadruplex structure within a duplex segment near the promoter region of theSMARCA4 gene”. Prof Eritja hightlighs the contribution to this work by Dr. Raimundo Gargallo from the University of Barcelona. The manuscript described the structural analysis of the promoter region of the SMARCA4 gene involved in ovarian cancer. This promoter region has an exceptionally long G-rich sequence.[...]

05 Nov

How to take advantage of the body’s natural processes to create innovative therapies?

During the month of October took place the Spanish Society of atherosclerosis (SEA 2020) Virtual meetings, promoted by Novartis. Prof. Ramon Eritja, Scientific Director of NANBIOSIS U29 Oligonucleotide Synthesis Platform (OSP) (from CIBERBBN at IQAC_CSIC), was the guess speaker in the session “Innovation and future therapeutic strategies in dyslipidemia” giving the conference entitled “How to take advantage of the body’s natural processes to create innovative therapies“, in the telematic congress of the Spanish society of atherosclerosis (SEA 2020) in the session “Innovation and future therapeutic strategies in dyslipidemia”.Dr. Ramon Eritja, explained the mechanism of action of some new drugs based[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

09 Apr

NANBIOSIS U2, U3 & U29 participate in the POC4CoV project to develop diagnostic technologies for SARS-COV-2

The Spanish Higher Council for Scientific Research (CSIC) will finance the project Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV), whose objective is to have effective diagnostic technologies for Covid-19. The Institute of Microelectronics of Barcelona (IMB-CNM-CSIC), the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) and the Institute of Materials Science of Aragon (ICMA) participate in it. The POC4CoV project aims to develop Point-of-Care (POC) devices for the in vitro diagnosis of SARS-COV-2 infection quickly and reliably, thanks to the use of multiplexed systems and the use of particular biomolecular probes. To do this, POC technological platforms will b[...]

07 Feb

Ethylcellulose nanoparticles as new “in vitro” tool for cell transfection

Researchers of NANBIOSIS U12 Nanostructured liquid characterization unit and U29 Oligonucleotide Synthesis Platform (OSP) of CIBER-BBN at IQAC-CSIC have obtained successfully ethylcellulose nanoparticles with positive zeta potential formed from nano-emulsion complexation with an antisense oligonucleotide which result very promising complexes for “in vitro” cell transfection. A new non-viral gene delivery vector has been developed, based on ethylcellulose, an easily available and low cost carbohydrate polymer, “generally recognized as safe” by the FDA. Although ethylcellulose is nonionic, positively charged nanoparticle dispersions have been obtained using nano-emulsion templates in cationic:non-ionic surfactant-based systems. The nanoparticles have been successfully complexed with negatively charged phosphorothioate antisens[...]

26 Apr

Nanbiosis_U10_Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids
Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids

Jose Luis Pedraz, Scientific Director of Unit 10 of NANBIOSIS Drug Formulation unit and Ramon Eritja Scientific Director of Unit U29 of NANBIOSIS Oligonucleotide Synthesis Platform (OSP) (CIBER-BBN) have participated in the entrapment of cationic nioplexes in supramolecular hydrogels and the use of these materials for transfecting cells. This work is focused on entrapping cationic nioplexes within supramolecular hydrogels based on N-protected phenylalanine. To modulate the supramolecular hydrogel diffusion properties, hydrogels were easily tuned with ĸ-carrageenan (≤ 1%). These materials were fully characterized using rheology. The niosomal liberation in solution through hydrogels was monitored by fluorescence and this release was[...]

U29. Oligonucleotide Synthesis Platform
Read More